Advertisement

Chimerism pp 105-117 | Cite as

Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease

  • Alexa J. Siddon
  • Christopher A. Tormey
Chapter

Abstract

Hematopoietic progenitor cell (HPC; stem cell) transplants represent a key management option for patients with severe disorders, particularly benign or malignant hematological diseases. However, in order to successfully perform a stem cell transplant, it is vital to determine the optimal source of HPCs to serve as a graft, as well as understand the strengths and limitations of these products. Moreover, it is important to understand the potential complications associated with HPC. As such, the aims of this chapter are as follows: (1) to review the types of stem cell sources available for transplant and how they are collected, (2) to discuss HLA and ABO compatibility in the setting of HPC transplant, (3) to understand the potential side effects of stem cell engraftment/transplantation, and (4) to assess possible treatments for side effects that pertain to transfusion medicine and apheresis services.

Keywords

Hematopoietic progenitor cell transplant Stem cell transplant HLA compatibility ABO compatibility Graft-versus-host disease Donor lymphocyte infusion 

References

  1. 1.
    Wingard JR, Gastineau DA, Leather HL, et al. Hematopoietic progenitor cell transplantation: a clinician’s handbook. 2nd ed. Bethesda: AABB Press; 2016.Google Scholar
  2. 2.
    Preynat-Seauve O, Krause KH. Stem cell sources for regenerative medicine: the immunological point of view. Semin Immunopathol. 2011;33:519–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Jaing TH. Umbilical cord blood: a trustworthy source of multipotent stem cells for regenerative medicine. Cell Transplant. 2014;23:493–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Center for International Blood and Marrow Transplant Research (CIBMTR) homepage. Accessed at: https://www.cibmtr.org/Pages/index.aspx.
  5. 5.
    Weisdorf DJ. Reduced-intensity versus myeloablative allogeneic transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):321–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101:680–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    National Marrow Donor Program (NMDP) homepage. Accessed at: https://bethematch.org/.
  8. 8.
    Powley L, Brown C, Melis A, Li Y, Parkes G, Navarrete CV. Consideration of noninherited maternal Ags as permissible HLA mismatches in cord blood donor selection. Bone Marrow Transplant. 2016;51:675–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Van der Zanden HGM, Van Rood JJ, Oudshoorn M, Bakker JNA, Melis A, Brand A, Scaradavou A, Rubinstein P. Noninherited maternal antigens identify acceptable HLA mismatches: benefit to patients and cost-effectiveness for cord blood bank. Biol Blood Marrow Transplant. 2014;20:1791–5.CrossRefGoogle Scholar
  10. 10.
    Worel N, Kalhs P. AB0-incompatible allogeneic hematopoietic stem cell transplantation. Haematologica. 2008;93:1605–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Dahl D, Hahn A, Koenecke C, Heuft HG, Dammann E, Stadler M, Buchholz S, Krauter J, Eder M, Sykora KW, Klein C, Ganser A, Sauer M. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk. Transfusion. 2010;50:649–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. Immunol Rev. 2014;258:183–207.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bierman PJ, Warkentin P, Hutchins MR, Klassen LW. Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin. Leuk Lymphoma. 1993;9:169–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Stussi G, Halter J, Schanz U, Seebach JD. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apher Sci. 2006;35:59–69.CrossRefPubMedGoogle Scholar
  16. 16.
    Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher. 2018;33(1):108–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Lasky LC. The role of the laboratory in marrow manipulation. Arch Pathol Lab Med. 1991;115:293–8.PubMedGoogle Scholar
  18. 18.
    Hows J, Beddow K, Gordon-Smith E, Branch DR, Spruce W, Sniecinski I, Krance RA, Petz LD. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood. 1986;67:177–81.PubMedGoogle Scholar
  19. 19.
    Iwanaga S, Sakaguchi T, Nakanishi K, Furukuwa M, Ishizeki K, Kogawa K, Tsuji A. Passenger lymphocyte syndrome with hemophagocytic syndrome after peripheral blood stem-cell transplantation from an HLA-matched full biological sibling: case report. Transfus Apher Sci. 2012;47:355–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Cunard R, Marquez II, Ball ED, Nelson CL, Corringham S, Clopton P, Sanchez AP, Lane T, Ward DM. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants. Transfusion. 2014;54:1857–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010;17:493–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Subramaniam DS, Fowler DH, Pavletic SZ. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia. 2007;21:853–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200–6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.CrossRefPubMedGoogle Scholar
  28. 28.
    Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945.CrossRefPubMedGoogle Scholar
  29. 29.
    Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30.CrossRefPubMedGoogle Scholar
  30. 30.
    Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100(9):3108–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103(4):1548–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Halaburda K, Schmid C, Schaap N, Dazzi F, von dem Borne PA, Petersen E, Beelen D, Abayomi A, Volin L, Buzyn A, Gurman G, Bunjes D, Guglielmi C, Olavarria E, de Witte T. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant. 2013;48:837–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev. 2013;27:55–62.CrossRefPubMedGoogle Scholar
  34. 34.
    Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, Bregante S, Frassoni F, Casarino L, Verdiani S, Bacigalupo A. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112:219–27.CrossRefPubMedGoogle Scholar
  35. 35.
    Fung W, Eder AF, Spitalnik SL, Westhoff CM, editors. Technical manual. 19th ed. Bethesda: AABB Press; 2017.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyYale University School of MedicineNew HavenUSA
  2. 2.Pathology and Laboratory Medicine Service, VA Connecticut HealthCare SystemWest HavenUSA
  3. 3.Department of Laboratory MedicineYale University School of MedicineNew HavenUSA

Personalised recommendations